INVVY News and Press, Indivior PLC ADR From 05/31/18

SLOUGH, England and RICHMOND, Va. , May 31, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) announced today that Indivior Inc., its wholly owned subsidiary, received a subpoena from the Office of the Insurance Commissioner for the California Department of Insurance ("CDI") on ...

Analysis Focus: KERX We have followed Keryx (KERX) for a while now, and we note the following developments in the last few months - sNDA approval for Auryxia in IDA patients in NDD-CKD, (iron deficiency anemia in non dialysis dependent patients with chronic kidney disease), withdrawal o...

SLOUGH, England and RICHMOND, Va. , May 25, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it has filed a regulatory submission with Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE™ (buprenorphine extended-release) injection, for subcut...

SLOUGH, England , May 24, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that Mark Crossley , CFO, will participate in Jefferies 2018 Global Healthcare Conference on Tuesday, June 5th, 2018 , at 8:30 a.m. local time, in New York City . Crossley will discuss Indivior's ...

SLOUGH, England , May 14, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that its U.S. subsidiary, Indivior Inc., together with Aquestive Therapeutics, Inc. (formerly known as Monosol Rx, LLC), entered into a settlement agreement with Par ...

INDIVIOR PLC ADR (INVVY) Q1 2018 Results Earnings Conference Call May 02, 2018, 08:00 AM ET Executives Shaun Thaxter - Chief Executive Officer Mark Crossley - Chief Financial Officer Christian Heidbreder - Chief Scientific Officer Javier Rodriguez - Chief Legal Officer Analy...

Indivior PLC ADR ( OTCPK:INVVY ): Q1 EPS of $0.11 More news on: INDIVIOR PLC ADR, Earnings news and commentary, Healthcare stocks news, Read more ...

Health Canada Grants Priority Review Designation for SUBLOCADE™ SLOUGH, England and RICHMOND, Va. , April 20, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it has filed a New Drug Submission (NDS) with Health Canada's Therapeutic Drugs Directo...

Results from an open-label, long-term safety and tolerability study of Indivior PLC's ( OTCPK:INVVY +1.6% ) SUBLOCADE (buprenorphine extended-release) in patients with moderate-to-severe opioid use disorder demonstrated its positive effect on quality-of-life measures. The data were pres...

SLOUGH, United Kingdom and RICHMOND, Va. , April 13, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the presentation of results from RB-US-13-0003, a study which evaluated long-term treatment with once-monthly SUBLOCADE™ (buprenorphine extended-release) inject...